The device is aimed at transforming the diagnosis and management of diffuse liver diseases through advanced AI-driven MRI analysis.
The company announced the product launch, which has received CE and UKCA marks for use in the European Union and the United Kingdom, marking a significant milestone in liver disease diagnostics.
Chronic liver diseases pose a substantial health burden worldwide, contributing to millions of deaths annually, according to the World Health Organization. QP-Liver, powered by Quibim’s AI models, offers an automated liver segmentation and precise quantification of tissue fat and iron levels from MRI scans.
The technology, the company says, enables early disease detection, personalized treatment planning, and accurate monitoring, ultimately enhancing patient care outcomes.
Detailed fat and iron quantification
The platform’s post-processing solution uses multi-echo chemical shift sequences to automatically analyze abdominal MRI exams, providing detailed fat and iron quantification.
By generating parametric maps and voxel-wise resolution reports, QP-Liver ensures comprehensive analysis and comparison with normative data, offering invaluable insights into disease severity and progression.
Angel Alberich-Bayarri, co-founder and CEO of Quibim, explained the significance of QP-Liver in liver disease diagnosis. He said: “Coexistence of Fat and Iron in the liver is a risk factor for hepatocarcinoma, and these findings need to be managed early. QP-Liver represents a significant leap forward in liver imaging analysis.”
Beyond liver disease diagnostics
Additionally, Quibim’s says its collaboration with regulatory authorities underscores its commitment to advancing precision health globally.
Alberich-Bayarri added: “It is important to highlight that the mission to speed up real-life early detection of cancer and other diseases such as liver disease is truly an international group effort at every stage. We are acutely aware of the vital role our research, healthcare and pharmaceutical partners play in ensuring the technology gets used to treat patients, which is why getting regulatory backing for QP-Liver is such a milestone. We look forward to seeing the tool being used across the EU and in the UK in the near future.”
Quibim’s mission to transform imaging into a catalyst for precision health extends beyond liver disease diagnostics. The company’s suite of innovative products, including QP-Prostate and QP-Brain, address critical needs in oncology, neurology, and other medical specialties. These regulatory-cleared medical devices leverage advanced algorithms to translate imaging data into actionable insights, facilitating early disease detection and personalized patient care.
In addition to its groundbreaking products, Quibim has forged strategic partnerships with industry leaders like Merck KGaA and Phillips, further enhancing its impact in the field of precision medicine. These collaborations aim to develop imaging biomarkers for predicting cancer patient response to immunotherapy and launch AI-based imaging solutions for prostate exams, driving innovation and improving patient outcomes on a global scale.
